CiPA Initiative – Validation of Comprehensive In Vitro Proarrhythmia CiPA Assay
In a recent Think Tank Meeting, the FDA, the Health and Environmental Sciences Institute, and the Cardiac Safety Research Consortium (CSR) discussed the CiPA Initiative, a new paradigm to assess proarrhythmic risks. This new approach includes these components: Mechanistic approach The CiPA uses a mechanistic approach to evaluate proarrhythmic drugs. The tool improves drug development…
Read more